Case Studies, Pharmaceutical

Case Study – Unidose Nasal Spray Pump for Opioid Overdose

Although naloxone has long been available in injection format as a treatment for opioid overdose, administration relies on the presence of a suitably trained responder. This case study describes a collaborative drug repurposing project with Aptar Pharma to develop an easy-to-administer naloxone nasal spray. The resulting product has been successfully commercialized to broaden access to a life-saving therapeutic. Utilizing Aptar Pharma’s Unidose Liquid (UDS) system, it is primeless, reliable, and intuitive. Collaboration accelerated time to market for the nasal spray via the FDA’s 505(b)(2) Abbreviated Approval Pathway (U.S.) creating valuable intellectual property. The global market for the product is in excess of $350 million (2021).

Download Case Study - Unidose Nasal Spray pump for opioid overdose
8 Sep 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

18 Sep 2018

Aptar Pharma provides guidance on FDA regulatory framework for OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 Jun 2018

Connected Medicine: Insights from Payers and Other Stakeholders

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
1 Apr 2018

A track record of success for nasal drug delivery in drug repurposing

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
16 Sep 2016

The Nasal Drug Delivery Journey: from Systemic to Nose-to-Brain?

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 24 25 26 27

Request Access

Close

Requesting access to Case Study – Unidose Nasal Spray Pump for Opioid Overdose.

  • This field is for validation purposes and should be left unchanged.
Back To Top